Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 601–700 of 963
Improving the quality of life in patients with Alzheimer's disease.
Howe, E. G. (2008) · Europe PMC (PubMed Central) · Cited by 12
Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist
Klunk, W. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1281 · Cited by 13
Self-citationPrimary progressive aphasia and the growing role of biomarkers in neurological diagnosis
Cummings, J. L. (2008) · Annals of Neurology · doi:10.1002/ana.21487 · Cited by 16
Cummings, J. L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.01.015 · Cited by 12
“Similarly, PIB appears to reliably identify the presence of Aß in the brain and cerebral blood vessels and to distinguish AD from non–amyloid-related conditions [14,15].”
O espectro clínico e laboratorial da doença de Alzheimer: Uma perspectiva neurológica
Moreira, M. A., & Moreira, S. V. (2020) · Revista Psicologia em Pesquisa · doi:10.34019/1982-1247.2020.v14.30649 · Cited by 20
Slee, M. G., Scotney, J., Rainey‐Smith, S. R., Erickson, K. I., Sohrabi, H. R., Verdile, G., & Brown, B. M. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102956 · Cited by 186
Sasaki, Y., Kimura, N., Aso, Y., Yabuuchi, K., Aikawa, M., & Matsubara, E. (2021) · Biomolecules · doi:10.3390/biom11101496 · Cited by 12
“One possible explanation for this discrepancy is that PiB-PET mainly detects insoluble fibrillar Aβ deposits [49].”
BackgroundThiophene-Based Ligands for Specific Assignment of Distinct Aβ Pathologies in Alzheimer's Disease
Klingstedt, T., Lantz, L., Shirani, H., Ge, J., Hanrieder, J., Vidal, R., Ghetti, B. F., & Nilsson, K. P. R. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00021 · Cited by 15
Peccati, F., Wiśniewska, M., Solans‐Monfort, X., & Sodupe, M. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp07274c · Cited by 11
Neurodegenerative Diseases: The Value of Early Predictive End Points
Hsieh, S. J., Alexopoulou, Z., Mehrotra, N., Struyk, A. F., & Stoch, S. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2544 · Cited by 11
“Quantitative and visual assessments of amyloid PET scans taken at different stages of AD progression reveal a consistent spatial and temporal pattern of tracer retention consistent with pathologically established amyloid plaque progression.(9) Several therapeutics targeting brain plaque, including bapineuzumab, ganten…”
BackgroundIdentifying Mild Alzheimer's Disease With First 30-Min 11C-PiB PET Scan
Shen, C., Wang, Z., Chen, H., Bai, Y., Li, X., Liang, D., Liu, X., Zheng, H., Wang, M., Yang, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.785495 · Cited by 12
“Previous studies suggested that PiB may be unable to detect AD variants characterized by diffuse β-amyloid plaques as it binds specifically to fibrillar β-amyloid deposition (Bacskai et al., 2007; Ikonomovic et al., 2008).”
BackgroundDriving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
Bayat, S., & Roe, C. M. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01109-1 · Cited by 12
“AD biomarkers and driving: progress to date In the late 1900s and early 2000s, positron emission tomography (PET) and cerebrospinal fluid collection (CSF) biomarkers of AD were tested and validated and later became the leading tools to detect AD pathology in vivo at the early stages [17, 18].”
BackgroundVascular cognitive impairment: dementia biology and translational animal models.
Barone, F. C., Rosenbaum, D. M., Zhou, J., & Crystal, H. (2009) · PubMed · Cited by 11
Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study
Initiative, J. A. D. N., Okada, Y., Kato, T., Iwata, K., Kimura, Y., Nakamura, A., Hattori, H., Toyama, H., Ishii, K., Ishii, K., et al. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01420-2 · Cited by 11
“All ROI values were transformed into SUVRs by dividing them by the average ROI value in the cerebellar cortex as reference, because 6-CN-PiB binding to diffuse amyloid plaques in the cerebellum cortex was not detectable in a pathological study [2].”
MethodDeveloping univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition
Wang, G., Dong, Q., Wu, J., Su, Y., Chen, K., Su, Q., Zhang, X., Hao, J., Yao, T., Liu, L., et al. (2020) · Medical Image Analysis · doi:10.1016/j.media.2020.101877 · Cited by 13
“fibrillar amyloid-β PET measurements using Pittsburgh Compound B (PiB) (Ikonomovic et al., 2008) and cerebrospinal fluid (CSF) amyloid β1−42 levels (Fagan et al.”
MethodDementia in Germany: Past Trends and Future Developments
Ziegler, U. (2011) · DZNE Pub · doi:10.18453/rosdok_id00000815 · Cited by 13
Strobel, J., Yousefzadeh‐Nowshahr, E., Deininger, K., Bohn, K. P., Arnim, C. A. F. V., Otto, M., Solbach, C., Anderl‐Straub, S., Polivka, D., Fissler, P., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12071460 · Cited by 11
Molecular Probes: From Aβ Imaging to Phototherapy in Alzheimer’s Disease
Jiang, Z., Wang, H., Jiang, Y., Gu, S., Yan, J., & Ran, C. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00860 · Cited by 11
The efficacy and limitation of lumboperitoneal shunt in normal pressure hydrocephalus
Liu, J.-T., & Su, P. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105748 · Cited by 10
Yousefzadeh‐Nowshahr, E., Winter, G., Bohn, P., Kneer, K., Arnim, C. A. F. V., Otto, M., Solbach, C., Anderl‐Straub, S., Polivka, D., Fissler, P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266906 · Cited by 10
Li, W., Sun, L., Yue, L., & Xiao, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-66195-7 · Cited by 10
Glia-Mediated Retinal Neuroinflammation as a Biomarker in Alzheimer's Disease
Madeira, M. H., Ambrósio, A. F., & Santiago, A. R. (2015) · Ophthalmic Research · doi:10.1159/000440887 · Cited by 11
Molecular neuroimaging in degenerative dementias
Jiménez-Bonilla, J. F., & CARRIL, J. M. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2013.07.027 · Cited by 12
Szalárdy, L., Zádori, D., Klivènyi, P., & Vécsei, L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160037 · Cited by 11
β-amyloid PET neuroimaging: A review of radiopharmaceutical development
Dupont, A.-C., Ribeiro, M.-J., Guilloteau, D., & Arlicot, N. (2017) · Médecine Nucléaire · doi:10.1016/j.mednuc.2016.12.002 · Cited by 11
Free Energy Profile for Penetration of Pittsburgh Compound-B into the Amyloid β Fibril
Zou, R., Kuang, G., Ågren, H., Nordberg, A. K., Långström, B., & Tu, Y. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00662 · Cited by 10
A vascular approach to mild amnestic cognitive impairment: a pilot study
Fromm, A., Lundervold, A. J., Moen, G., Skulstad, S. M., & Thomassen, L. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12054 · Cited by 11
“Amyloid angiopathy also shows an association with AD (22).”
BackgroundKincses, Z. T., Király, A., Veréb, D., & Vécsei, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143195 · Cited by 11
Oh, M., Seo, M., Oh, S. Y., Kim, H., Choi, B. W., Oh, J. S., & Kim, J. S. (2018) · Neuroreport · doi:10.1097/wnr.0000000000000986 · Cited by 10
Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease
Grimmer, T., Alexopoulos, P., Tsolakidou, A. F., Guo, L., Henriksen, G., Yousefi, B. H., Förstl, H., Sorg, C., Kurz, A., Drzezga, A. E., et al. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/712048 · Cited by 12
“The Scientific World Journal Volume 2012, Article ID 712048, 6 pages doi:10.1100/2012/712048 The cientificWorldJOURNAL”
InfluentialPrevalence of dementia in a rural nursing home population in Southern Germany
Hutsteiner, P., Galler, S., Mendoza, M. C., & Klünemann, H. H. (2013) · The European Journal of Psychiatry · doi:10.4321/s0213-61632013000300003 · Cited by 10
Amyloid Imaging: Liberal or Conservative? Let the Data Decide
Jagust, W. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.152 · Cited by 11
Wood, J. I., Dulewicz, M., Szadziewska, A., Weiner, S., Ge, J., Stringer, K. M., Desai, S., Fenson, L., Piotrowska, D., Brinkmalm, G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63328-y · Cited by 14
“Most importantly, these early effects of A β aggregation, including synaptic changes, precede the development of mature A β plaques that can be detected by PET imaging or by CSF analysis 11 – 13 .”
Whatever Happened to Pittsburgh Compound-A?
Klunk, W. E., & Mathis, C. A. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318188c0c8 · Cited by 12
“This has now been confirmed by 2 correlative autopsy studies in other patients.(25,26) Perhaps it would be overstating the importance of this first subject to the development of amyloid imaging to suggest that she deserves a place beside the woman who provided the very first ‘‘images’’ of AD before the disease even ha…”
ResultSelf-citationAdvanced Neuroimaging Methods Towards Characterization of Early Stages of Alzheimer’s Disease
Sepulcre, J., & Masdeu, J. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_31 · Cited by 11
Devina, T., Wong, Y., Hsiao, C., Li, Y., Lien, C., & Cheng, I. H.-J. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15687 · Cited by 9
Liu, F., Shi, Y., Wu, Q., Chen, H., Wang, Y., Cai, L., & Zhang, N. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14418 · Cited by 11
Triumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Dybing, K. M., Vetter, C. J., Dempsey, D. A., Chaudhuri, S., Saykin, A. J., & Risacher, S. L. (2024) · Journal of Neurotrauma · doi:10.1089/neu.2024.0055 · Cited by 9
La neuroimagen molecular en las demencias degenerativas
Jiménez-Bonilla, J. F., & CARRIL, J. M. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2013.06.012 · Cited by 15
Preclinical Alzheimer's disease
Gil‐Gregorio, P., & Yubero, R. (2014) · Reviews in Clinical Gerontology · doi:10.1017/s095925981400001x · Cited by 9
[(11)C]PiB PET in Gerstmann-Sträussler-Scheinker disease.
Deters, K., Risacher, S. L., Yoder, K. K., Oblak, A. L., Unverzagt, F. W., Murrell, J. R., Epperson, F., Tallman, E. F., Quaid, K. A., Farlow, M. R., et al. (2016) · Europe PMC (PubMed Central) · Cited by 15
Is there Still a Place for Perfusion SPECT in the Diagnosis of Dementia?
Ebmeier, K. P. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010040 · Cited by 9
“Examples for this are imaging of the dopamine transporter in dementia of the Lewy body type [34] or amyloid imaging in AD [35].”
MethodAmyloid deposition in semantic dementia: a positron emission tomography study
Brown, E. E., Graff‐Guerrero, A., Houle, S., Mizrahi, R., Wilson, A. A., Pollock, B. G., Mulsant, B. H., Felsky, D., Voineskos, A. N., Tang‐Wai, D. F., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4423 · Cited by 10
“The benzothiazole radiotracer Pittsburgh compound B ([11C]-PIB) allows in vivo assessment of cerebral amyloid-β (Aβ) burden (Wang et al., 2002; Ikonomovic et al., 2008; Leinonen et al., 2008).”
BackgroundKrivinko, J. M., Erickson, S. L., Abrahamson, E. E., Wills, Z. P., Ikonomović, M. D., Penzes, P., & Sweet, R. A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.006 · Cited by 9
“Ab1-42 peptide concentration was quantified in diethylamine (DEA)-soluble Ab fractions as described previously (Ikonomovic et al., 2008).”
MethodSelf-citationPET amiloide en enfermedades neurodegenerativas que cursan con demencia
Camacho, V., Gómez‐Grande, A., Sopeña, P., García-Solís, D., Río, M. G., Lorenzo‐Bosquet, C., Rubí, S., & Arbizu, J. (2018) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2018.03.004 · Cited by 13
Diabetes mellitus and cognitive impairment
Surkova, E. V., Tanashyan, M. М., Bespalov, A. I., & Naminov, A. V. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.10.000362 · Cited by 10
Iwata, N., Tsubuki, S., Sekiguchi, M., Watanabe-Iwata, K., Matsuba, Y., Kamano, N., Fujioka, R., Takamura, R., Watamura, N., Kakiya, N., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402650 · Cited by 8
Klingstedt, T., Shirani, H., Parvin, F., Nyström, S., Hammarström, P., Graff, C., Ingelsson, M., Vidal, R., Ghetti, B. F., Sehlin, D., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108032 · Cited by 10
“…shown poor binding to A b deposits in certain brain regions and reduced binding to brain homogenates despite evidence of an overall high A b load (26 – 28), as well as a limited ability to detect cotton wool plaques (CWPs), a certain type of A b deposits found in cases of diAD associated with…”
Ye, R., Kivisäkk, P., Goodheart, A. E., Fatima, H. A., Peterec, E., Thibault, E. G., Properzi, M. J., Johnson, K. A., Arnold, S. E., & Gomperts, S. N. (2025) · Movement Disorders · doi:10.1002/mds.30238 · Cited by 8
“32,33,38 Our observation that plasma pTau181 correlated with PiB retention in cortical regions susceptible to amyloid pathology, including the FLR aggregate regions, as well as inferior temporal, inferior frontal, and frontal pole, 2 indicates that plasma pTau181 may re fl ect early deposition of…”
Antibody engagement with amyloid‐beta does not inhibit [ 11 C]PiB binding for PET imaging
Xiong, M., Dahlén, A. D., Roshanbin, S., Wik, E., Aguilar, X., Eriksson, J., Sehlin, D., & Syvänen, S. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16127 · Cited by 9
“They bind primarily to amyloid structures found predominantly in fibrillar forms of A β (Frieg et al., 2020 ; Ikonomovic et al., 2008 ), although weaker binding to diffuse A β pathology is also present (Ikonomovic et al., 2020 ).”
Davies‐Jenkins, C. W., Workman, C. I., Hupfeld, K. E., Zöllner, H. J., Leoutsakos, J., Kraut, M. A., Barker, P. B., Smith, G. S., & Oeltzschner, G. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.06.003 · Cited by 8
Cerebrospinal Fluid β-Amyloid and Dynabridging in Alzheimer's Disease Drug Development
Ereshefsky, L., Jhee, S. S., Yen, M., Moran, S., Pretorius, S., & Adams, J. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.39 · Cited by 8
Sauerbeck, J., Ishii, K., Hosokawa, C., Kaida, H., Scheiwein, F., Hanaoka, K., Rominger, A., Brendel, M., Bartenstein, P., & Murakami, T. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1258-8 · Cited by 8
Qin, Q., Fu, L., Wang, R., Lyu, J., Ma, H., Zhan, M., Zhou, A., Wang, F., Zuo, X., & Wei, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.732159 · Cited by 8
Identification of Multicolor Fluorescent Probes for Heterogeneous Aβ Deposits in Alzheimer’s Disease
Mukherjee, A., Al‐Lahham, R., Corkins, M. E., Samanta, S., Schmeichel, A. M., Singer, W., Low, P. A., Govindaraju, T., & Soto, C. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.802614 · Cited by 8
Santillán-Morales, V., Rodríguez-Espinosa, N., Muñoz‐Estrada, J., Alarcón-Elizalde, S., Acebes, Á., & Benítez‐King, G. (2024) · Brain Sciences · doi:10.3390/brainsci14010046 · Cited by 10
Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories
Ackley, S. F., Hayes‐Larson, E., Brenowitz, W. D., Swinnerton, K. N., Mungas, D., Fletcher, E. M., Singh, B., Whitmer, R. A., DeCarli, C. S., & Glymour, M. M. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102713 · Cited by 8
“, 2002), it has been possible to visualize amyloid plaques in vivo, as well as quantify total amyloid burden in the brain (Ikonomovic et al., 2008).”
BackgroundArakawa, Y., Nai, Y., Shidahara, M., Furumoto, S., Seki, C., Okamura, N., Tashiro, M., Kudo, Y., Yanai, K., Gonda, K., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183566 · Cited by 8
Pardo, J. V., Lee, J. T., & Initiative, A. D. N. (2018) · eNeuro · doi:10.1523/eneuro.0396-17.2018 · Cited by 10
Polyglucosan Bodies in Aged Brain and Neurodegeneration: Cause or Consequence?
Rai, A., & Ganesh, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-3585-3_4 · Cited by 11
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2019) · doi:10.1101/639054 · Cited by 7
Cohen, A. D., & Villemagne, V. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70291 · Cited by 7
“…the cortex of individuals with AD or DLB primarily reflects Α β -related cerebral amyloidosis, rather than binding to Lewy bodies (LB) or NFT. 85,86,88,90 11 C-PiB has consistently provided valuable quantitative data on insoluble Α β burden in vivo, improving the understanding of Α β deposition in…”
Folloso, M. C., Villaraza, S. G., Yi-Wen, L., Khong, P., Tanaka, T., Hilal, S., Venketasubramanian, N., & Chen, C. (2024) · International Journal of Stroke · doi:10.1177/17474930241252556 · Cited by 9
“8,36,37 This limits the ability of [ 11 C]-PiB to totally “rule out” amyloid pathology.”
BackgroundMethodWhen Does Alzheimer’s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-Á., Cervera‐Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19305 · Cited by 8
Sussman, B. L., Wyckoff, S. N., Heim, J., Wilfong, A. A., Adelson, P. D., Kruer, M. C., Gonzalez, M. J., & Boerwinkle, V. L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.847834 · Cited by 7
“Neurodegeneration in Alzheimer’s disease is primarily cortical with some subcortical neurodegeneration (27) while Parkinson’s disease neurodegeneration is largely within BG (23).”
BackgroundAnkul Singh, S., Ansari, M. N., Elossaily, G. M., Vellapandian, C., & Prajapati, B. G. (2024) · ACS Omega · doi:10.1021/acsomega.3c06328 · Cited by 8
Measuring disease progression in corticobasal syndrome
Huang, N., Hornberger, M., Hodges, J. R., & Burrell, J. R. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7389-5 · Cited by 7
Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery
Mercier, J., Provins, L., & Hannestad, J. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12437-0 · Cited by 8
Bao, Y., Shea, Y. F., Chiu, P. K., Kwan, J. S. K., Chan, F. H.-W., & Mak, H. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-14532-z · Cited by 7
Shokouhi, S., Campbell, D. L., Brill, A. B., Gwirtsman, H. E., & Initiative, T. A. D. N. (2016) · Brain Pathology · doi:10.1111/bpa.12399 · Cited by 7
“As these radiotracers target predominately the classic cored and neuritic Ab plaques, which are not frequently present in the cerebellum (11, 30, 37), the whole cerebellum or the cerebellar gray matter have served as reference regions for the majority of Ab-PET studies to date.”
BackgroundPositron Emission Tomography in Alzheimer Disease
Schmidt, M. E., Matthews, D. C., Andrews, R. D., & Mosconi, L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00005-6 · Cited by 7
The Challenge of Defining Alzheimer Disease Based on Biomarkers in the Absence of Symptoms
Gómez‐Isla, T., & Frosch, M. P. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1667 · Cited by 7
Hatashita, S., & Wakebe, D. (2021) · Medicine · doi:10.1097/md.0000000000027055 · Cited by 7
Imaging Tau Pathology—The Next Step
Jagust, W. J. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0520 · Cited by 7
The challenging concept of preclinical Alzheimer's disease
Wallon, D., & Garnier‐Crussard, A. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.07.016 · Cited by 7
Development of [124/125I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
Reddy, T. T., Iguban, M. H., Melkonyan, L. L., Shergill, J., Liang, C., & Mukherjee, J. (2023) · Molecules · doi:10.3390/molecules28020865 · Cited by 6
Les marqueurs de la maladie d’Alzheimer prodromale
de Souza, L. C., Sarazin, M., Uspenskaya, O., Habert, M., Lamari, F., Lehéricy, S., & Dubois, B. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.005 · Cited by 6
Salem, H., Rocha, N. P., Colpo, G. D., & Teixeira, A. L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160250 · Cited by 6
Radiotracers Used to Image the Brains of Patients with Alzheimer’s Disease
George, N., Gean, E. G., Nandi, A., Brašić, J. R., & Wong, D. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00016-6 · Cited by 7
Genetic and degenerative disorders primarily causing dementia
Masdeu, J. C., & Pascual, B. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00026-x · Cited by 6
“The regional retention of PIB-like compounds reflects the regional density of abeta plaques (Bacskai et al., 2007; Ikonomovic et al., 2008; Kadir et al., 2011; Choi et al., 2012).”
Piri, R., Naghavi‐Behzad, M., Gerke, O., Høilund‐Carlsen, P. F., & Vafaee, M. S. (2019) · Clinical and Translational Imaging · doi:10.1007/s40336-019-00339-y · Cited by 6
Pivtoraiko, V. N., Racic, T., Abrahamson, E. E., Villemagne, V. L., Handen, B. L., Lott, I. T., Head, E., & Ikonomović, M. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.728739 · Cited by 7
Self-citationNew Diagnostic Criteria for Alzheimer‘s Disease
Zetterberg, H. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.46 · Cited by 6
The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly
Kollack‐Walker, S., Liu, C. Y., & Fleisher, A. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.010 · Cited by 6
Tateishi, M., Kitajima, M., Hirai, T., Yoneda, T., Hashimoto, M., Kurehana, N., Uetani, H., Fukuhara, R., Azuma, M., & Yamashita, Y. (2018) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2017-0134 · Cited by 6
Grinberg, L. T. (2022) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 6
Neurocognitive Dysfunction in Old Diabetes: Management and Treatment
Umegaki, H. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_33 · Cited by 7
Grimmer, T., Drzezga, A. E., & Kurz, A. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-2951-6 · Cited by 7
Ringman, J. M., Teplow, D. B., & Villemagne, V. L. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fe11f · Cited by 6
Li, F., Cheng, J., Jin, K., Zhao, L., Li, J., Wu, J., & Ren, X. (2024) · Brain and Behavior · doi:10.1002/brb3.70111 · Cited by 8
“The tracer 11C-PIB is known for its strong correlation with neuroinflammatory plaquesandvascularamyloid,asshowninautopsies(Ikonomovic et al. 2008).”
BackgroundZeiss, C. J., Huttner, A. J., Nairn, A. C., Arnsten, A. F. T., Datta, D., Strittmatter, S. M., Wyk, B. V., & Duque, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251323787 · Cited by 5
“61 This extent of PiB uptake exceeds the optimal cutoff (PiB DVR of 1.14) associated with future cognitive decline.”
InfluentialYeo, J. M., Waddell, B., Khan, Z. H., & Pal, S. (2015) · Cited by 5
A kinetics-based approach to amyloid PET semi-quantification
Chincarini, A., Peira, E., Corosu, M., Morbelli, S. D., Bauckneht, M., Capitanio, S., Pardini, M., Arnaldi, D., Vellani, C., D’Ambrosio, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04689-y · Cited by 6
Joseph‐Mathurin, N., & Raji, C. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_23 · Cited by 5
Sha, S. J., & Rabinovici, G. D. (2016) · Wiley eBooks · doi:10.1002/9781118797662.ch3 · Cited by 5
Fluorescent Markers for Amyloid‐β Detection: Computational Insights
Peccati, F., Pantaleone, S., Solans‐Monfort, X., & Sodupe, M. (2016) · Israel Journal of Chemistry · doi:10.1002/ijch.201600114 · Cited by 5
Challenges in Alzheimer’s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences
Lombardi, G., Pupi, A., Bessi, V., Polito, C., Padiglioni, S., Ferrari, C., Lucidi, G., Berti, V., Cristofaro, M. T. D., Piaceri, I., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200119 · Cited by 8
“Results from an autopsy-confirmed study showed that in AD brain tis-suesections,6-CN-PiB(highlyfluorescentPittsburgh compoundBderivative)labelingwasmostrobustin compact/coredplaquesthanindiffuseplaques[75].”
Interval‐based features of auditory ERPs for diagnosis of early Alzheimer's disease
Sabbaghi, N., Sheikhani, A., Noroozıan, M., & Sabbaghi, N. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12191 · Cited by 7
Neurological imaging: statistics behind the pictures
Dinov, I. D. (2011) · Imaging in Medicine · doi:10.2217/iim.11.37 · Cited by 6
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.